A phase II study of FOLFOX combined with nab-paclitaxel in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: a Big Ten Cancer Research Consortium trial.
Marie S DreyerMary MulcahyMasha KocherginskyYolande ChenHoward S HochsterPashtoon M KasiSheetal KircherEmil LouYangruijue MaNataliya V UbohaAl Bowen BensonPublished in: The oncologist (2024)
FOLFOX-A has a significant response rate, expected toxicities, and should be considered for future investigation in combination with immunotherapy given the recent approvals.
Keyphrases
- phase ii study
- locally advanced
- squamous cell carcinoma
- rectal cancer
- open label
- papillary thyroid
- metastatic colorectal cancer
- radiation therapy
- small cell lung cancer
- study protocol
- phase iii
- big data
- phase ii
- squamous cell
- advanced non small cell lung cancer
- machine learning
- lymph node metastasis
- combination therapy
- artificial intelligence
- deep learning
- replacement therapy
- childhood cancer
- epidermal growth factor receptor